Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vincasar PFS
(United States) [Available]Synonyms :
22-oxovincaleukoblastin, 22-oxovincaleukoblastine, leurocristine, vincristin, vincristina, vincristine, vincristinum
Class :
Antineoplastic agents and Vinca Alkaloid
Brand Name :
Vincasar PFS
(United States) [Available]Synonyms :
22-oxovincaleukoblastin, 22-oxovincaleukoblastine, leurocristine, vincristin, vincristina, vincristine, vincristinum
Class :
Antineoplastic agents and Vinca Alkaloid
Dosage Forms & Strengths
Injectable solution
1mg per ml
1.4
mg/m^2
Intravenous (IV)
over one minute once a week
1.4
mg/m^2
Intravenous (IV)
over one minute once a week
Use:
Acute leukemia
This drug shows significant use when combined with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas, and Wilms' tumor.
Comment:
The manufacturer recommends the dose.
Dosage Forms & Strengths
Injectable solution
1mg per ml
The recommended dose for <18 years and <10 kg :
0.05
mg/kg
Intravenous (IV)
over one minute once a week as an initial dose
2 mg/m2 IV given over one minute once a week as the maximum dose
The recommended dose for<18 years and >10 kg: 1-2 mg/m2 IV given over one minute once a week
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased effect of immunosuppressive activities of fingolimod
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased therapeutic efficacy of the measles virus vaccine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased level of serum concentration of vincristine
when both drugs are combined, there may be a decreased therapeutic efficacy of the rotavirus vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased therapeutic efficacy of the smallpox vaccine
when both drugs are combined, there may be a reduced excretion rate of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of peripheral neuropathy
vincristine: they may enhance the serum concentration of glycoprotein Inhibitors
the effect of vincristine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vincristine
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
vincristine is known to increase the risk of peripheral neuropathy when combined with lipegfilgrastim
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be a reduced metabolism of vincristine
when both drugs are combined, there may be an increased effect of immunosuppressive activities of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be an increased level of serum concentration of vincristine
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased effect of immunosuppressive activities of vincristine
when both drugs are combined, there may be a decreased metabolism of vincristine
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may diminish the excretion rate when combined with vinca alkoloids, resulting in an enhanced serum level
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
there is an increased risk of myopathy, myoglobinuria, and rhabdomyolysis when vincristine is combined with ciprofibrate
the risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can increase when vincristine is combined with alendronic acid
when combined with vincristine, the excretion of cholecystokinin may be decreased
when both drugs are combined, there may be a high metabolism of vincristine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of nerve damage
may enhance the immunosuppressive effects of each other
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
coadministration of ancestim with vincristine might increase the risk of peripheral neuropathy
when lenograstim is taken with vincristine, the risk or severity of peripheral neuropathy is enhanced
when both drugs are combined, there may be a decreased metabolism of vincristine
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of myopathy, rhabdomyolysis, and myoglobinuria
Actions and Spectrum:
Actions:
Vincristine is a natural vinca alkaloid that works as an antimicrotubule agent. It stops cell division by trapping cells in the metaphase. These drugs work by stopping the formation of microtubules by preventing tubulin from joining together and causing the breakdown of already-formed tubules. Vinca alkaloids specifically target the M phase and S phase of the cell cycle.
Spectrum:
Vincristine is an approved treatment for adults and children with acute leukemia. Additionally, it is utilized in the management of various cancers, such as Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Ongoing research is exploring the potential use of vincristine in treating other types of cancer.
Frequency defined
>10%
Alopecia
Frequency Not Defined
Acute uric acid nephropathy
Aspermia
Amenorrhea
Constipation
Gait changes
Hypertension
Hypotension
Jaw pain
Loss of deep-tendon reflexes
Myelosuppression
Nausea
Peripheral neuropathy
Paresthesia
Paralytic ileus
Leukopenia
Sensory loss
Vomiting
Black Box Warning:
If the medication leaks from the vein, it can harm the nearby tissue, a condition known as extravasation. Although not common, it’s crucial to address it promptly. Inform your nurse immediately if you experience stinging, pain, redness, or swelling around the vein. If these symptoms occur after you return home, contact your doctor or nurse using the provided telephone number right away.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pharmacology:
Vincristine, a vinca alkaloid, disrupts microtubule formation during cell division’s metaphase, causing mitotic arrest. Key pharmacological features include inhibiting microtubules by binding to tubulin, acting in cell cycle phases such as the S and M phases, inducing mitotic arrest through crystallization, and exerting cytotoxic effects, especially on rapidly dividing cancer cells.
Pharmacodynamics:
Vinca alkaloids, like vinblastine, work during the cell cycle phases such as the S and M phases by preventing the formation of microtubules, leading to the inhibition of DNA and RNA synthesis.
Pharmacokinetics:
Distribution
Protein-bound is 75%
The volume of distribution is 215 L/1.73 m2
Metabolism
Hepatic (CYP 450 3A action)
Elimination and Excretion
The half-life is 23-85 hours
The drug is excreted 80% in feces and 10-20% in urine.
Administration:
Vincristine is typically administered intravenously (IV). It should never be administered intrathecally (into the spinal fluid), as this can be fatal.
Pronunciation: vin-kri-sti-n
Why do we use vincristine?
Vincristine is a chemotherapy medication used to treat a variety of cancers, including Wilms tumor, lymphoma, neuroblastoma, and leukemia. It belongs to the vinca alkaloid group, which slows or stops the growth of cancer cells by interfering with their ability to divide.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
